UNSPSC 51411901: Aminoxytriphene or amotriphene

This classification denotes a vasodilating agent and antiarrhythmic agent with the molecular formula C26H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VO63T4936, chemically known as 2,3,3-tris(p-methoxyphenyl)-n,n-dimethylallylamine but generally known as aminoxytriphene, which bears US NIH Compound Identifier 11283. European Medicines Agency schedules Aminoxytriphene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05450MIG.

UNSPSC 51411901 Aminoxytriphene or amotriphene is a Commodity code representing specific pharmaceutical active ingredients procured by state and local health and emergency-services agencies. State and local governments buying under this code source emergency medications and advanced life support drugs for fire rescue, emergency medical services, and health-benefit programs, typically in bulk quantities with strict expiration and quality-assurance requirements. Issuing bodies include municipal purchasing departments (city fire and rescue services), state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The Tampa Fire Rescue procurement illustrates the operational scope: the City of Tampa's Purchasing Department solicited sealed bids for emergency medications including epinephrine, adenosine, diltiazem, and labetalol for use by Tampa Fire Rescue, with strict nine-month minimum expiration dating, ten-calendar-day delivery timelines, and 365-day defect warranties. Cooperative purchasing entities also drive activity under this code; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements.

Recent activity spans Florida and the Upper Midwest, with Texas health authorities issuing exploratory RFIs on direct-to-manufacturer pharmacy programs. The City of Tampa's sealed-bid solicitation (26P00188, due April 8, 2026) carried an estimated contract value of $40,000 with a one-year term and optional two-year renewals, including a 5 percent bid discount for Small Local Business Enterprise participation. The MMCAP RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products with a two-year term, requiring vendors to achieve 75 percent evaluation weight on price competitiveness and to pay 3 percent administrative fees on contract purchases. Both solicitations emphasize compliance documentation—Safety Data Sheets under OSHA standards, WCAG 2.2 accessibility conformance, and FDA requirements with minimum one-year shelf life from manufacture. The Texas Health and Human Services Commission's RFI (HHS0017013, closed April 3, 2026) signals emerging state interest in direct-to-manufacturer prescription programs outside traditional PBM and GPO arrangements.